← All trials
NCT03135015
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2017
- Primary completion
- Jun 21, 2017
- Completion date
- Jun 21, 2017
- First posted
- May 1, 2017
- Last posted
- Apr 20, 2020
- Enrollment
- 22
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Housey Healthcare ULCLead sponsor
- Glycemic Index Laboratories, IncCollaborator
- Glycemic Index Laboratories, IncOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.